To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell transplantation

Trial Details

NCT ID
NCT07280494
Phase
PHASE1
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CAR-T Therapy
Locations (sample)
  • Beijing, China, China|39.9075,116.39723

Key Eligibility Criteria

  • (1) The subject or the legal guardian understands and voluntarily signs the informed consent form (ICF).
  • (2) Male or female, age ≥ 3 years at the time of signing the informed consent form.
  • (3) Expected survival period of no less than 12 weeks. (4) ECOG performance score of 0-2 at the time of signing the ICF. (5) Confirmed as relapsed/…
  • Bone marrow morphology examination at screening shows the proportion of primitive immature lymphocytes in the bone marrow \< 5%, and positive for m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →